Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Change in Accured Expenses for 14 consecutive years, with -$57.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 18.75% year-over-year to -$57.0 million; the TTM figure through Mar 2026 stood at $15.0 million (down 56.57% YoY), while the FY2025 annual figure was $24.0 million, down 48.94% from the prior year.
• Change in Accured Expenses retreated to -$57.0 million in Q1 2026 per RARE's latest filing, from $37.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $57.4 million in Q2 2022 and bottomed at -$57.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $5.5 million across 5 years, with a median of $11.2 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 375.52% — and 2025, when it tumbled 140.02%.
• Ultragenyx Pharmaceutical's Change in Accured Expenses stood at $27.4 million in 2022, then tumbled by 44.49% to $15.2 million in 2023, then jumped by 204.72% to $46.4 million in 2024, then retreated by 20.22% to $37.0 million in 2025, then slumped by 254.0% to -$57.0 million in 2026.
• Business Quant data shows RARE's Change in Accured Expenses at -$57.0 million in Q1 2026, $37.0 million in Q4 2025, and $45.1 million in Q3 2025.